RNAC · Cartesian Therapeutics, Inc.
$9.99
-0.20 (-1.96%)
At close · Aug 27
Market Cap
$308.30M
Shares
30.26M
Cartesian Therapeutics, Inc. Earnings Call Transcripts
Quarterly earnings calls for Cartesian Therapeutics, Inc. (RNAC), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲636.9%
$6.65M
−$14.89M
'19 Q4
20-03-12
▼100%
$
−$19.62M
'20 Q1
20-05-07
▼100%
$
−$24.08M
'20 Q2
20-08-06
·
$4.65M
−$9.73M
'20 Q3
20-11-05
▲79.6%
$11.95M
−$15.45M
'20 Q4
21-03-11
·
$11.05M
−$24.60M
'21 Q1
21-05-13
·
$19.66M
$4.57M
'21 Q2
21-08-12
▲425.8%
$24.43M
−$17.89M
'21 Q3
21-11-09
▲150.5%
$29.94M
$12.24M
'21 Q4
22-03-10
▲207.7%
$34.00M
$28.78M
'22 Q1
22-05-05
▲99.7%
$39.27M
$8.60M
'22 Q2
22-08-04
▼15.2%
$20.71M
−$7.89M
'22 Q3
22-11-03
▼86.6%
$5.25M
−$11.39M
'23 Q2
23-08-17
LATEST
▼81.2%
$1.10M
−$17.71M
'25 Q1
25-05-08
Conference
Investor event
2026-05-19
Cartesian Therapeutics, Inc. (RNAC) May 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-04-13
Cartesian Therapeutics, Inc. (RNAC) April 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q1
2025-05-08
Cartesian Therapeutics, Inc. (RNAC) Q1 2025 Earnings Call Transcript
Confident tone
Pipeline expansion into myositis
Safety profile advantage vs. DNA CAR-Ts
Lead Asset Descartes-8 in Myasthenia Gravis
Revenue
$1.10M
▼ 81.2% YoY Diluted EPS
$-0.68
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-17
Cartesian Therapeutics, Inc. (RNAC) Q2 2023 Earnings Call
Revenue
$5.25M
▼ 86.6% YoY Diluted EPS
$-2.23
▼ 223.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q3
2022-11-03
Cartesian Therapeutics, Inc. (RNAC) Q3 2022 Earnings Call
Revenue
$20.71M
▼ 15.2% YoY Diluted EPS
$-1.50
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Cartesian Therapeutics, Inc. (RNAC) Q2 2022 Earnings Call
Revenue
$39.27M
▲ 99.7% YoY Diluted EPS
$1.80
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Cartesian Therapeutics, Inc. (RNAC) Q1 2022 Earnings Call
Revenue
$34.00M
▲ 207.7% YoY Diluted EPS
$2.40
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-10
Cartesian Therapeutics, Inc. (RNAC) Q4 2021 Earnings Call
Revenue
$29.94M*
▲ 150.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-09
Cartesian Therapeutics, Inc. (RNAC) Q3 2021 Earnings Call
Revenue
$24.43M
▲ 425.8% YoY Diluted EPS
$-4.80
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-12
Cartesian Therapeutics, Inc. (RNAC) Q2 2021 Earnings Call
Revenue
$19.66M
Diluted EPS
$0.00
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-13
Cartesian Therapeutics, Inc. (RNAC) Q1 2021 Earnings Call
Revenue
$11.05M
Diluted EPS
$-6.60
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-03-11
Cartesian Therapeutics, Inc. (RNAC) Q4 2020 Earnings Call
Revenue
$11.95M*
▲ 79.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Cartesian Therapeutics, Inc. (RNAC) Q3 2020 Earnings Call
Revenue
$4.65M
Diluted EPS
$-2.70
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Cartesian Therapeutics, Inc. (RNAC) Q2 2020 Earnings Call
Revenue
$
▼ 100% YoY Diluted EPS
$-7.50
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-07
Cartesian Therapeutics, Inc. (RNAC) Q1 2020 Earnings Call
Revenue
$
▼ 100% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-03-12
Cartesian Therapeutics, Inc. (RNAC) Q4 2019 Earnings Call
Revenue
$6.65M
▲ 636.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–16 of 16 earnings calls
Key facts
CIK
1453687
CUSIP
816212302
13F (30d)
86 filings
85 filers
Visit website
Investor relations